# A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome

> **NCT00287079** · PHASE3 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 35 (actual)

## Conditions studied

- Clinically Isolated Syndrome

## Interventions

- **DRUG:** Rebif®
- **OTHER:** No Treatment

## Key facts

- **NCT ID:** NCT00287079
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2013-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00287079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00287079, "A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00287079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*